On this page
The evidence at a glance
The study, in context
CohBar’s 2021 announcement concerns CB4211, an investigational MOTS-c analogue. Its early safety and exploratory biomarker findings cannot be transferred directly to commercially listed native MOTS-c.
CohBar: CB4211 phase 1a/1b topline announcement (August 2021)
- Study design
- Company-reported randomized, double-blind, placebo-controlled early-phase study.
- Who or what was studied
- The four-week phase 1b cohort included 11 active-treatment and nine placebo participants.
- What was measured
- Primarily safety/tolerability, with exploratory metabolic and liver measures.
- What it found
- Sponsor reported no serious adverse events and exploratory biomarker changes; liver fat decreased in both groups.
- Important limit
- Sponsor topline announcement, small short cohort, analogue rather than native MOTS-c; no established long-term clinical benefit.
Identify the molecule before the outcome
The distinction between endogenous peptide and product remains essential here. CB4211 is an analogue, not simply another supplier’s name for a native MOTS-c vial. A related structure can motivate investigation without making every finding interchangeable. The research should retain the investigational molecule’s own name.
A provider detail worth checking
Rx Peps Direct lists native MOTS-c rather than CB4211. Keep the analogue distinction visible when evaluating the evidence behind its listing.
A biomarker can move without proving a lasting benefit
Exploratory laboratory measures can help researchers choose future questions. They do not establish fewer clinical events, durable weight change or improved daily function. Short duration and a small cohort also limit what can be learned about uncommon harms. Those constraints belong beside the reported signal, not in a distant disclaimer.
Remember who released the result
A sponsor announcement is a primary account of what the company reported. It is not the same thing as a peer-reviewed full trial report with enough detail to appraise every analysis. Treat the announcement as an early record, and avoid selecting its most favorable measure while ignoring the rest of the comparison.
What the shopping pages add—and what they do not
Cienega Medical describes a MOTS-c bottle offering with a separate review fee. Rx Peps Direct lists a defined vial and additional order charges. These facts can make service comparisons more useful. They do not establish that either product reproduces CB4211 exposure or its reported findings.
Build a better question for the clinician
Ask whether the proposed exact formulation has matching human evidence, how uncertainty is explained and what follow-up would address. Use the cost planner only after a quote defines the product and purchasing unit. An analogue’s early trial should not be converted into a predicted metabolic result for an individual consumer.
Common questions
Was CB4211 the same as a native MOTS-c vial?
No. The sponsor described CB4211 as an investigational analogue.
Do the exploratory biomarkers establish lasting weight loss?
No. They do not establish durable clinical outcomes for native MOTS-c products.
Sources & further reading
Primary research, provider documents and policy sources used in this article. Sources do not endorse this publication.
Source review: 2026-10-29. Provider terms and policy documents can change.